The rights to the technology and items for application beyond ophthalmology will end up being retained by the previous shareholders of ESBATech and spun off right into a separate new organization, Delenex Therapeutics AG.. Alcon to acquire ESBATech AG Alcon announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology organization. Alcon can pay ESBATech shareholders $150 million in money at closing, plus contingent payments as high as $439 million based on the achievement of upcoming research and advancement milestones that would be expected to create worth for Alcon.GAAP SG&A expenditures were $63.5 million for Q4 2010, in comparison to $51.9 million for Q4 2009. Full Season 2010 Non-GAAP Financial Results: The Company reported non-GAAP net gain of $167.3 million in 2010 2010, or $1.78 per share, compared to non-GAAP net gain of $108.4 million, or $1.18 per talk about, in ’09 2009. Alexion’s non-GAAP working expenses for the entire year 2010 were $294.1 million, in comparison to $225.9 million for 2009. Non-GAAP R&D expenditures for 2010 2010 were $90.4 million, in comparison to $72.9 million for the prior year. The increase in R&D expenses primarily reflected the growth of the business’s clinical trial programs.